Senti Biosciences (NASDAQ:SNTI) Posts Quarterly Earnings Results, Misses Expectations By $0.10 EPS

Senti Biosciences (NASDAQ:SNTI) announced its earnings results on Friday. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.10), FiscalAI reports. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $1.00 million.

Senti Biosciences Stock Performance

NASDAQ SNTI opened at $0.79 on Friday. The company has a market capitalization of $20.77 million, a P/E ratio of -0.25 and a beta of 2.12. Senti Biosciences has a one year low of $0.79 and a one year high of $5.10. The stock has a 50 day moving average price of $0.95 and a 200-day moving average price of $1.38.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SNTI. Armistice Capital LLC purchased a new position in shares of Senti Biosciences during the second quarter valued at approximately $1,883,000. Geode Capital Management LLC raised its holdings in shares of Senti Biosciences by 395.6% in the second quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock worth $311,000 after buying an additional 117,588 shares during the period. Citadel Advisors LLC bought a new stake in shares of Senti Biosciences during the 3rd quarter worth approximately $117,000. Virtu Financial LLC bought a new stake in shares of Senti Biosciences during the 4th quarter worth approximately $46,000. Finally, Jane Street Group LLC purchased a new position in Senti Biosciences during the 4th quarter valued at $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on SNTI. Chardan Capital upped their price objective on Senti Biosciences from $12.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, December 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $9.00.

About Senti Biosciences

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.